Cath Lab Safety Push; Eplontersen Fails ATTR-CM; Testosterone Risks

A multisociety expert consensus statement released this week advocates for the broader adoption of advanced radiation protection devices for professionals working in cardiac catheterization laboratories. This recommendation stems from ongoing concerns about cumulative radiation exposure among cath lab operators. The statement, published in JACC: Cardiovascular Interventions, aims to establish clearer guidelines and promote best practices to mitigate these occupational hazards.

In parallel, the drug Eplontersen has failed to demonstrate efficacy in a key clinical trial for transthyretin amyloid cardiomyopathy (ATTR-CM). Data from the trial indicated that Eplontersen did not meet its primary or secondary endpoints, signifying a setback for its potential use in treating this serious cardiac condition. This outcome contrasts with earlier hopes for the drug's therapeutic promise in patients suffering from ATTR-CM.

Furthermore, the use of testosterone therapy for off-label indications is raising concerns regarding potential risks. While testosterone has approved uses, its administration for unapproved conditions is associated with a spectrum of adverse effects that warrant careful consideration. Healthcare providers are urged to exercise caution and thoroughly assess the risk-benefit profile before prescribing testosterone for non-indicated purposes. The full implications of these findings are still being evaluated by the medical community.